Want to see BEAM full AI Analyst Report?
Total Valuation
Beam Therapeutics has a market cap or net worth of $3.53B. The enterprise value is $3.30B.
Market Cap$3.53B
Enterprise Value$3.30B
Share Statistics
Beam Therapeutics has 102,879,210 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding102,879,210
Owned by Insiders3.39%
Owned by Institutions46.72%
Financial Efficiency
Beam Therapeutics’s return on equity (ROE) is -0.06 and return on invested capital (ROIC) is -27.43%.
Return on Equity (ROE)-0.06
Return on Assets (ROA)-0.05
Return on Invested Capital (ROIC)-27.43%
Return on Capital Employed (ROCE)-0.28
Revenue Per Employee355.58K
Profits Per Employee-203.54K
Employee Count393
Asset Turnover0.09
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Beam Therapeutics is ―. Beam Therapeutics’s PEG ratio is 0.42.
PE Ratio―
PS Ratio19.62
PB Ratio2.21
Price to Fair Value2.21
Price to FCF-7.61
Price to Operating Cash Flow-9.69
PEG Ratio0.42
Income Statement
In the last 12 months, Beam Therapeutics had revenue of 139.74M and earned -79.99M in profits. Earnings per share was -0.81.
Revenue139.74M
Gross Profit117.45M
Operating Income-383.69M
Pretax Income-79.99M
Net Income-79.99M
EBITDA-29.92M
Earnings Per Share (EPS)-0.81
Cash Flow
In the last 12 months, operating cash flow was -369.73M and capital expenditures -14.11M, giving a free cash flow of -383.84M billion.
Operating Cash Flow-369.73M
Free Cash Flow-383.84M
Free Cash Flow per Share-3.73
Dividends & Yields
Beam Therapeutics pays an annual dividend of $0.225, resulting in a dividend yield of ―
Dividend Per Share$0.225
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.27
52-Week Price Change95.78%
50-Day Moving Average30.69
200-Day Moving Average27.36
Relative Strength Index (RSI)60.74
Average Volume (3m)2.05M
Important Dates
Beam Therapeutics upcoming earnings date is Aug 11, 2026, Before Open (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 11, 2026
Ex-Dividend Date―
Financial Position
Beam Therapeutics as a current ratio of 13.09, with Debt / Equity ratio of 21.54%
Current Ratio13.09
Quick Ratio13.09
Debt to Market Cap0.06
Net Debt to EBITDA0.04
Interest Coverage Ratio-8.77
Taxes
In the past 12 months, Beam Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Beam Therapeutics EV to EBITDA ratio is -91.59, with an EV/FCF ratio of -7.61.
EV to Sales19.61
EV to EBITDA-91.59
EV to Free Cash Flow-7.61
EV to Operating Cash Flow-7.94
Balance Sheet
Beam Therapeutics has $1.21B in cash and marketable securities with $250.82M in debt, giving a net cash position of $960.83M billion.
Cash & Marketable Securities$1.21B
Total Debt$250.82M
Net Cash$960.83M
Net Cash Per Share$9.34
Tangible Book Value Per Share$12.52
Margins
Gross margin is -32.43%, with operating margin of -274.57%, and net profit margin of -57.24%.
Gross Margin-32.43%
Operating Margin-274.57%
Pretax Margin-57.24%
Net Profit Margin-57.24%
EBITDA Margin-21.41%
EBIT Margin-25.95%
Analyst Forecast
The average price target for Beam Therapeutics is $52.91, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$52.91
Price Target Upside68.55% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast157.97%
EPS Growth Forecast86.11%